ATOPIC DERMATITIS | PFIZER B7451029 | PHASE III

Status: FULLY RECRUITED

Drug: PF-04965842 & DUPILUMAB

Timeline: 11 visits over 24 weeks

Detailed Description

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of PF-04965842 and Dupilumab in pediatric subjects from 6 to 17 years of age with moderate to severe plaque psoriasis.

Inclusion

• Informed consent
• Male or Female
• Age > 18 yrs
• Diagnosis of Atopic Dermatitis for at least 1 yr before screening

Exclusions

• Female subjects who are pregnant or lactating
• Significant medical history

If you’re interested in participating, please SEND US AN EMAIL AND/OR CONTACT US and our research team will be in touch.